PolmanCHReingoldSCBanwellBClanetMCohenJAFilippiM. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69: 292–302.
2.
LublinFDBaierMCutterG. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology2003; 61: 1528–1532.
3.
VercellinoMRomagnoloAMattiodaAMaseraSPiacentinoCMerolaA. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand2009; 119: 126–130.
4.
HirstCIngramGPearsonOPickersgillTScoldingNRobertsonN. Contribution of relapses to disability in multiple sclerosis. J Neurol2008; 255: 280–287.
5.
WeinshenkerBGRiceGPNoseworthyJHCarriereWBaskervilleJEbersGC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain1991; 114: 1045–1056.
6.
WeinshenkerBGBassBRiceGPNoseworthyJCarriereWBaskervilleJ. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain1989; 112: 1419–1428.
7.
MarrieRACutterG. Relapses in multiple sclerosis: important or not?Neurology2009; 73: 1612–1613.
8.
ConfavreuxCVukusicSAdeleineP. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain2003; 126: 770–782.
9.
ConfavreuxCVukusicSMoreauTAdeleineP. Relapses and progression of disability in multiple sclerosis. N Engl J Med2000; 343: 1430–1438.
10.
TremlettHYousefiMDevonshireVRieckmannPZhaoY. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology2009; 73: 1616–1623.
11.
ScalfariANeuhausADegenhardtARiceGPMuraroPADaumerM. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain2010; 133: 1914–1929.
12.
LublinFDReingoldSC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology1996; 46: 907–911.
13.
KremenchutzkyMRiceGPBaskervilleJWingerchukDMEbersGC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain2006; 129: 584–594.
14.
WolinskyJSNarayanaPAO’ConnorPCoylePKFordCJohnsonK. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol2007; 61: 14–24.
15.
HawkerKO’ConnorPFreedmanMSCalabresiPAAntelJSimonJ. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol2009; 66: 460–471.
16.
FabianMTLublinFWolinskyJ. Evaluation of progressive relapsing MS patients in the PROMISE Trial. Neurology2011; 76: A613.
